Remove tag pharma-manufacturing
article thumbnail

Pharma Pulse 3/29/24: Super Micro’s AI Boom Carries a Big Price Tag, Leveraging Digital Tools to Optimize Manufacturing & more

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What Tech Trends Do Life Sciences Marketers Need to Know About?

PM360

Another capability made possible by fine-tuning is the enhancement of content tagging. Content tagging has always been a labor-intensive task. Auto-tagging ensures that the right content efficiently reaches the right customers. Fine-tuning models can target domains and generate prompts to tag the content into relevant topics.

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Supply chain challenges take many forms in pharma – from capacity issues, to managing excess safety stock, and ensuring accurate supplier communication. Neil Keegan is head of manufacturing at Automata, a London-based biotech company providing robotic automation solutions to the life sciences industry. About the author.

Pharma 96
article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

Source: Fierce Pharma If that enthusiasm pans out in the long run, it could mean at least 300,000 patients taking the drug, or $10 billion to $15 billion in peak Aduhelm from U.S. Not to mention the $56,000 annual price tag. neurologists or psychiatrists currently treating about 12,000 Alzheimer’s patients. government.

FDA 218
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 This is not the first treatment to come with a high price tag.

Marketing 105
article thumbnail

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

PM360

Importance of Data Collection Many manufacturers fail to allocate sufficient time to obtain the safety and efficacy data needed to define critical endpoints. This option grows more critical as new therapies become available with price tags as high as $3.5 Cutting corners on data collection can be another costly error.